[go: up one dir, main page]

WO1996013267A3 - Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome - Google Patents

Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome Download PDF

Info

Publication number
WO1996013267A3
WO1996013267A3 PCT/US1995/013624 US9513624W WO9613267A3 WO 1996013267 A3 WO1996013267 A3 WO 1996013267A3 US 9513624 W US9513624 W US 9513624W WO 9613267 A3 WO9613267 A3 WO 9613267A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
brimonidine
glaucoma
derivatives
prostaglandins
Prior art date
Application number
PCT/US1995/013624
Other languages
English (en)
Other versions
WO1996013267A2 (fr
Inventor
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO1996013267A2 publication Critical patent/WO1996013267A2/fr
Publication of WO1996013267A3 publication Critical patent/WO1996013267A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des combinaisons d'agents adrénergiques alpha tels que la brimonidine et ses dérivés tels que représentés par la formule (I), dans laquelle chaque Y est choisi séparément dans le groupe consistant en N, N-CH3, O, S et C-R1; R1 représente hydrogène, oxo ou alkyle inférieur; R2, R3 et R4 sont choisis séparément dans le groupe consistant en hydrogène, halogène, alkyle inférieur et alcényle inférieur; n vaut un entier de 1 à 3; et une ligne en pointillés à côté d'une ligne pleine indique soit une liaison simple soit une liaison double, à condition que lorsque n=1, les deux liaisons entre Y et C-R1 ne puissent être des liaisons doubles, et des prostaglandines connues en soi utilisées pour induire une baisse de la pression intraoculaire. Ces combinaisons sont utiles dans des compositions, des méthodes de traitement et des articles produits, destinés au traitement du glaucome et à l'atténuation d'une pression intraoculaire élevée.
PCT/US1995/013624 1994-10-27 1995-10-20 Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome WO1996013267A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33005094A 1994-10-27 1994-10-27
US08/330,050 1994-10-27

Publications (2)

Publication Number Publication Date
WO1996013267A2 WO1996013267A2 (fr) 1996-05-09
WO1996013267A3 true WO1996013267A3 (fr) 1996-07-04

Family

ID=23288106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013624 WO1996013267A2 (fr) 1994-10-27 1995-10-20 Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome

Country Status (1)

Country Link
WO (1) WO1996013267A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
WO1998020881A1 (fr) 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-cetal-prostaglandines pour le traitement du glaucome ou de l'hypertension oculaire
EP0968183A2 (fr) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
WO2004073708A1 (fr) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide et brimonidine pour le traitement d'etats oculaires
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
EP2329849B1 (fr) 2009-11-18 2015-04-29 Galderma Research & Development Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011117378A2 (fr) 2010-03-26 2011-09-29 Galderma Research & Development Methodes et compositions ameliorées pour le traitement sûr et efficace de la télangiectasie
KR101707704B1 (ko) 2010-03-26 2017-02-16 갈데르마 리써어치 앤드 디벨로프먼트 홍반의 유효하고 안전한 치료를 위한 개선된 방법 및 조성물
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
BR112013009578B1 (pt) 2010-10-21 2020-10-20 Galderma S.A. composição tópica em gel e uso de uma composição tópica em gel
US20130023536A1 (en) * 2011-07-20 2013-01-24 Graham Richard S Fixed dose combination of bimatoprost and brimonidine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (fr) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (fr) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERLE JB: "Pharmacological advances in the treatment of glaucoma.", DRUGS AGING, SEP 1994, 5 (3) P156-70, NEW ZEALAND *

Also Published As

Publication number Publication date
WO1996013267A2 (fr) 1996-05-09

Similar Documents

Publication Publication Date Title
WO1996013267A3 (fr) Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome
EP1225168A3 (fr) Dérivés de prostaglandines pour le traitement du glaucome et de l'hypertension oculaire
TR200003844T2 (tr) Epotilon türevleri, sentezleri ve kullanımları
MY121967A (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
GEP20115347B (en) Heterocyclocarboxamide derivatives
IL157773A0 (en) 2-amino-propanol derivatives
BG103485A (en) Ketobanzamides as calpain inhibitors
MY113022A (en) Novel pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
AU688628B2 (en) Novel amidinonaphthyl derivative or salt thereof
MXPA03004165A (es) Mezclas de caucho que contienen gel con peroxidos inorganicos.
AU3192195A (en) Thiazolidinedione derivatives, their production and use
WO1996013259A3 (fr) Procede et combinaisons servant a inhiber les proteine kinases
CA2416867A1 (fr) Cyclopentanoindoles, compositions contenant de tels composes et procedes de traitement
CA2057464A1 (fr) Terpolymeres de l'ethylene, leur preparation et leur utilisation comme additifs de distillats d'huile minerale
HU9503401D0 (en) Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives
CA2221110A1 (fr) Utilisation de derives d'acide cyclopentane heptan(ene)oique, 2-heteroarylalkenyle en tant qu'agents therapeutiques pour le traitement de l'hypertension oculaire
EP0437030A3 (en) Use of 4-substituted imidazoles for lowering intraocular pressure
HK1049479A1 (zh) 降眼壓類脂類
NZ506497A (en) Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension
TW427913B (en) Eye drop composition comprising pilocarpine and a β-blocking agent and process making the same
MY132550A (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
CA2048010A1 (fr) Derives de la proline
AU6597790A (en) Use of 6- or 7-hydroxyindole derivatives as couplers and dyeing compositions and methods using these
MY100512A (en) New 6-or 7-methlenandrosta-1, 4-diene-3, 17-dione derivatives and process for their preparation.
WO2004019874A3 (fr) Composes de 5-chroman-5-yl-ethylamine substitues et leur utilisation dans le traitement du glaucome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase